Our AI-algorithm allows prediction of antibody-antigen binding based solely on the primary structure of the proteins, and harness developments in cell-free protein synthesis technology that enable the high-throughput generation of a large, customized proprietary antibody cluster. The submitted antibody sequences maximize the antibodies’ therapeutic potential while minimizing safety and manufacturing risks.